Biothera Pharmaceutical Inc. Appoints Barry Labinger As Chief Executive Officer

EAGAN, Minn.--(BUSINESS WIRE)--Biothera Pharmaceutical Inc. announced today the appointment of Barry Labinger as Chief Executive Officer, effective December 14. Biothera Pharmaceutical is developing a novel cancer immunotherapy that triggers a robust, coordinated immune response against a wide range of cancers.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.